Krystal Biotech (KRYS) news
Recent news
Krystal Biotech, Inc.: RBC initiates coverage with outperform rating; target price $400
RBC Capital Markets has initiated coverage of Krystal Biotech, Inc. (NASDAQ: KRBK) with an "outperform" rating and a target price of $400 per share. The firm cited the company’s progress in advancing its lead gene therapy candidate, KB105, for the treatment of recessive dystrophic epidermolysis…
AInvest Wire · Aug 14, 2026Krystal Biotech shares down 7.2% after Q2 results
Krystal Biotech (NASDAQ: KRYS) shares fell 7.2% following the release of its second-quarter 2026 financial results, despite strong revenue growth and continued expansion of its flagship product, VYJUVEK. The company reported $119.2 million in product revenue for the quarter, up from $96.0 million…
AInvest Wire · Aug 3, 2026Krystal Biotech Q2 EPS USD 1.79
AInvest Wire · Aug 3, 2026Krystal Biotech - sees FY 2026 non-GAAP R&D and SG&A expense $175 mln-$195 mln
AInvest Wire · Aug 3, 2026Krystal Biotech 2Q EPS $1.79, est. $1.70
AInvest Wire · Aug 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.